Sino Biopharma’s M&A move pays off with big licensing deal
The Chinese drugmaker stands to gain more than $7 billion from a partnership with Germany’s Boehringer if its therapies can deliver clinical and commercial results Key Takeaways: Most of the…
Legend Biotech shares tumble as Carvykti outlook overshadows profit
Cancer treatment developer Legend Biotech Corp. (LEGN.US) reported on Tuesday that its third-quarter revenue rose 32% year-on-year to $359.5 million, while its net income reached $51.7 million, reversing a $39.6…
Akeso’s overseas drug promise fails to slow share decline
The Chinese drugmaker has been under pressure on equity markets since revealing plans for a share placement, overriding positive news for its key cancer therapy Key takeaways: Akeso’s shares have…
AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid
The company leads the field for recombinant proteins among its domestic peers, but overseas companies dominate the international market Key Takeaways: AcroBiosystems has applied to list in Hong Kong, reporting…
Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…